TIME FOR LIFE

Cancer genome research

Identifying key driver mutations and their proteomic impact is essential for new drug development. 
Cancer genome research is conducted on the basis of omics information (genomics, transcriptomics, proteomics etc.).


Direct determining of DNA structure by genome sequencing gives complete information about the mutational burden each cancer cell carries. These cells are exposed to a variety of evolutional selection pressures: decreased blood supply, hypoxia, treatment-related effects and so on. As a result, the selection and expansion of subclones with genetic makeup, that is ideal for continued survival.


Targeted cancer treatments are designed to attack cells with certain mutations. But if a targeted mutation occurs on an evolutionary branch and not the trunk, the chemotherapy will fail over the time. Treatment-resistant subclones will gain an evolutional advantage to dominate and spread.